BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27026370)

  • 1. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
    Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
    J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
    Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
    PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
    Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
    Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
    Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
    Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
    Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.
    Fu Y; Zhu JY; Richman A; Zhang Y; Xie X; Das JR; Li J; Ray PE; Han Z
    J Am Soc Nephrol; 2017 Apr; 28(4):1106-1116. PubMed ID: 27864430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
    Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
    Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tripartite complex of suPAR, APOL1 risk variants and α
    Hayek SS; Koh KH; Grams ME; Wei C; Ko YA; Li J; Samelko B; Lee H; Dande RR; Lee HW; Hahm E; Peev V; Tracy M; Tardi NJ; Gupta V; Altintas MM; Garborcauskas G; Stojanovic N; Winkler CA; Lipkowitz MS; Tin A; Inker LA; Levey AS; Zeier M; Freedman BI; Kopp JB; Skorecki K; Coresh J; Quyyumi AA; Sever S; Reiser J
    Nat Med; 2017 Aug; 23(8):945-953. PubMed ID: 28650456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
    Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
    Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
    Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
    Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
    Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
    Yang YW; Poudel B; Frederick J; Dhillon P; Shrestha R; Ma Z; Wu J; Okamoto K; Kopp JB; Booten SL; Gattis D; Watt AT; Palmer M; Aghajan M; Susztak K
    Mol Ther; 2022 Jul; 30(7):2491-2504. PubMed ID: 35450819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
    Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
    Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.
    McCarthy GM; Blasio A; Donovan OG; Schaller LB; Bock-Hughes A; Magraner JM; Suh JH; Tattersfield CF; Stillman IE; Shah SS; Zsengeller ZK; Subramanian B; Friedman DJ; Pollak MR
    Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34350953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
    Sharma AK; Friedman DJ; Pollak MR; Alper SL
    FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein domains of APOL1 and its risk variants.
    Lan X; Wen H; Lederman R; Malhotra A; Mikulak J; Popik W; Skorecki K; Singhal PC
    Exp Mol Pathol; 2015 Aug; 99(1):139-44. PubMed ID: 26091559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOL1 Kidney Disease Risk Variants: An Evolving Landscape.
    Dummer PD; Limou S; Rosenberg AZ; Heymann J; Nelson G; Winkler CA; Kopp JB
    Semin Nephrol; 2015 May; 35(3):222-36. PubMed ID: 26215860
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ma L; Chou JW; Snipes JA; Bharadwaj MS; Craddock AL; Cheng D; Weckerle A; Petrovic S; Hicks PJ; Hemal AK; Hawkins GA; Miller LD; Molina AJ; Langefeld CD; Murea M; Parks JS; Freedman BI
    J Am Soc Nephrol; 2017 Apr; 28(4):1093-1105. PubMed ID: 27821631
    [No Abstract]   [Full Text] [Related]  

  • 20. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy.
    Johnstone DB; Zhang J; George B; Léon C; Gachet C; Wong H; Parekh R; Holzman LB
    Mol Cell Biol; 2011 May; 31(10):2162-70. PubMed ID: 21402784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.